Eli Lilly and Company (NYSE:LLY) Shares Sold by Burns J W & Co. Inc. NY

Burns J W & Co. Inc. NY decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 4.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,331 shares of the company’s stock after selling 144 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Eli Lilly and Company were worth $2,572,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Quilter Plc grew its stake in Eli Lilly and Company by 9.9% in the 2nd quarter. Quilter Plc now owns 8,888 shares of the company’s stock valued at $8,047,000 after acquiring an additional 800 shares during the period. Brown Brothers Harriman & Co. grew its position in shares of Eli Lilly and Company by 16.2% in the second quarter. Brown Brothers Harriman & Co. now owns 18,660 shares of the company’s stock valued at $16,894,000 after purchasing an additional 2,599 shares during the period. Fairfield Financial Advisors LTD purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $12,866,000. Angeles Investment Advisors LLC increased its stake in shares of Eli Lilly and Company by 61.5% during the second quarter. Angeles Investment Advisors LLC now owns 1,085 shares of the company’s stock worth $982,000 after purchasing an additional 413 shares in the last quarter. Finally, Black Diamond Financial LLC raised its position in shares of Eli Lilly and Company by 41.1% during the 2nd quarter. Black Diamond Financial LLC now owns 1,522 shares of the company’s stock worth $1,378,000 after purchasing an additional 443 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LLY. Truist Financial raised their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Barclays decreased their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, Bank of America restated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Eli Lilly and Company Stock Down 0.3 %

Shares of NYSE:LLY opened at $797.17 on Tuesday. The firm has a fifty day moving average price of $785.91 and a 200 day moving average price of $858.62. Eli Lilly and Company has a 1-year low of $612.70 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock has a market cap of $756.77 billion, a P/E ratio of 86.18, a P/E/G ratio of 2.99 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter last year, the firm earned $0.10 EPS. The business’s revenue was up 20.4% on a year-over-year basis. Sell-side analysts predict that Eli Lilly and Company will post 13.18 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has approved a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.75%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 64.86%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.